9 completed, 1 terminated, 1 withdrawn. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 9, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow bavituximab: new trials by email Literature Review of bavituximab trials Research Report on bavituximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma Stereotactic Body Radiation Therapy (SBRT), Sorafenib, Bavituximab - HepatoCellular Carcinoma, Unresectable HepatoCellular Carcinoma | Phase 1 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2017-03-27 | 2020-06-05 | |
| A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma Radiation, Bavituximab, Capecitabine - Rectal Adenocarcinoma | Phase 1 | Completed | University of Texas Southwestern Medical Center | 15 | 2012-08-08 | 2020-08-20 |
| Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer Cabazitaxel plus bavituximab - Prostate Cancer, Prostatic Neoplasms | Phase 1 / Phase 2 | Terminated | Medical University of South Carolina | 4 | 2011-06-01 | 2018-07-13 |
| Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects Bavituximab - Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Completed | UNC Lineberger Comprehensive Cancer Center | 26 | 2011-05-01 | 2018-12-04 |
| Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection Bavituximab, Pegylated interferon (PEG-IFN) - Hepatitis C | Phase 1 / Phase 2 | Completed | Peregrine Pharmaceuticals | 66 | 2011-01-01 | 2012-02-06 |
| Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib - Hepatocellular Carcinoma, Liver Cancer | Phase 1 / Phase 2 | Completed | University of Texas Southwestern Medical Center | 47 | 2011-01-01 | 2020-11-12 |
| Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer paclitaxel, bavituximab, laboratory biomarker analysis - Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer | Phase 1 | Completed | University of Arizona | 14 | 2011-01-01 | 2016-04-21 |
| Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus bavituximab - Hepatitis C Virus, Hiv Infections | Phase 1 | Completed | Peregrine Pharmaceuticals | 24 | 2007-07-01 | 2011-06-09 |
| Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C bavituximab - Hepatitis C | Phase 1 | Completed | Peregrine Pharmaceuticals | 24 | 2006-05-01 | 2008-05-07 |
| Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection Bavituximab - Hepatitis C | Phase 1 | Completed | Peregrine Pharmaceuticals | 32 | 2005-08-01 | 2008-05-07 |
| Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies Bavituximab - Tumors | Phase 1 | Completed | Peregrine Pharmaceuticals | 28 | 2005-06-01 | 2011-03-01 |
Hepatitis C (4) · Carcinoma, Hepatocellular (2) · Liver Neoplasms (2) · Neoplasms (2) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Non-Small-Cell Lung (1) · Fibrosis (1) · Gastrointestinal Neoplasms (1) · HIV Infections (1) · Hepatitis (1) · Liver Diseases (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1)
Peregrine Pharmaceuticals (5) · University of Texas Southwestern Medical Center (2) · H. Lee Moffitt Cancer Center and Research Institute (1) · Medical University of South Carolina (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Arizona (1)
United States (10) · Georgia (1)
Adam C Yopp, MD (1) · Alison Stopeck (1) · David E Gerber, MD (1) · Eliot W Godofsky, MD (1) · Eliot W Godofsky, MD, FACP (1) · Eric Lawitz, MD (1) · Janet Nuttall, MPH (1) · Jessica Frakes, M.D. (1) · Jihad Slim, MD (1) · Jorge Rodriguez, MD (1) · Juneko Grilley Olson, MD (1) · Lee Rosen, MD (1) · Lee S Schwartzberg, MD, FACP (1) · Linda Garland, MD (1) · Lucas Wong, MD (1)
P30CA023074 (1)